Name

Leuprolide Acetate

Alternate Names

Abbott-43818
Carcinil
Eligard
Leuprolide
Leuprorelin
Lupron
Lupron Depot
Lupron TAP
TAP-144
Viadur

Abbreviations

None

Category

Hormones and hormonal mechanisms

Subcategory

Gonadotropin-releasing hormone agonist

NSC Number

377526

Primary Site

Prostate cancer
See remarks for other site information
Breast
Ovary

Histology

None

Remarks

December 2016 Update: Lupron as ovarian suppressor in pre-menopausal breast cancer has been approved by the FDA per NCI. Beginning with cases diagnosed 1/1/2017 forward, code as hormone therapy.

Lupron is a gonadotropin-releasing hormone analogue. FDA approved its use on prostate cancer and should be coded as hormone therapy.

FOR BREAST CASES DIAGNOSED 1/1/2017 FORWARD: Code as hormone treatment

FOR BREAST CASES DIAGNOSED PRIOR TO 1/1/2017:
The effectiveness of Lupron on patients with breast cancer was being studied in one clinical trial. This trial was looking at extended endocrine therapy for pre-menopausal women with breast cancer. This trial is looking at the drug combination of letrozole and leuprolide for women who have taken Tamoxifen for at least 4-5 years. This drug combination is used in the treatment for metastatic breast cancer and is sometimes used for treatment of early stage breast cancer. However, as of early December 2016 it has not been accepted as a standard of care treatment and had not yet received FDA approval for treatment of breast cancer. While it may not have received FDA approval, it can be used "off label" for other conditions. Lupron should be coded as "Other Therapy" until such time that it receives FDA approval.

Coding

Please see remarks for additional information
Glossary